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ESOPHAGEAL CANCER 
Dr. Edward Yu 
 
A. Incidence: <5/100,000 in U.S. ; <10/100,000 in Canada. 
gastroesophageal cancer of adenocarcinoma  is  on the rise as compare 
to  squamous cell carcinoma of the esophagus. 
 
B. Risk factors: Tylosis, Plummer-Vinson Syndrome, Caustic Injury,   
    Achalasia, Smoking, Alcohol. 
 
C. Basic patient Work Up requires the following: 
History & Physical 
Barium swallow 
Endoscopy 
CBC, Blood chemistry 
Chest x-ray , Chest /Abdominal CT 
Endoscopic U/S 
Pathology 
  
X-ray of a patient with lower third esophageal cancer.(barium filling defects) 
 
 
 
D. Esophageal cancer staging uses TNM system: 
 
Staging (TNM): 
x T1           Tumor invades lamina propria or submucosa. 
x T2                 Tumor invades muscularis propria. 
x T3           Tumor invades adventitia. 
x T4               Tumor invades adjacent structures. 
x N1           Regional nodes mets. 
 
Staging (TNM): 
stage I       T1, N0 
stage II      A- T2-3, N0  ;  B-T1-2,  N1 
stage III    T3-4,  N1 
stage IV     M1  ( including Celiac nodes involvement). 
 
 
E. Esophageal cancer management modality options: 
 
1. Surgery: 
x Aim is to achieve R0 resection (complete resection of tumor). 
x The 5 yr. survival after R0 resection is 15-20%. 
x The median survival is about 18 months. 
 
2. Radiation Therapy: 
x Randomized prospective trial ( Radiation Therapy Oncology Group-
RTOG 8501 ) showed  that radiation alone of 64Gy at 2Gy/fx, 3yr. 
survival  rate  is zero. 
x Radiation therapy alone reserved for palliation or  for medically 
unable to receive chemotherapy. 
x Pre-op. or post-op. radiation therapy has been shown to have   no 
survival benefit. 
x Post-op radiation therapy can offer   local control benefit  in high 
risk patients.( Fok et  al,Surg 1993,Teniere et al., Surg Gyn 1991). 
 
3.  Chemoradiation: 
x Randomized prospective trial (RTOG 8501) also showed that 
combined chemo (5FU/Cisp) + radiation therapy (50Gy) has 
survival benefit  over  radiation therapy (64Gy) alone. 
x The 5 yr. overall survival (OS ) of combined modality is superior   
(27%)  than radiation therapy alone (0%) , median  survival 14 
mos.(month) of combined  versus (VS) 9 mos. of radiation alone. 
x Local failure rate of combined chemoradiation  is   also superior ( 
47% )  over  radiation alone(  65%). 
x Higher dose of radiation  therapy (64.8Gy)  with  same chemo 
showed no additional benefit :  median OS  with   higher radiation 
dose of 13 mos VS  standard 50 Gy of 18.1 mos. not-significance ( 
NS), 2 yr. OS of  31% VS 40%   (NS), and local/regional failure of  
56% VS 52% ( NS). 
x Presently research focus on  new investigational agents : 
paclitaxel- based, docetaxel-based, or irinotecan-based 
chemotherapy to improve overall survival. 
 
 
Randomized Control Trials (RCTs )comparing pre-op chemoradiation 
therapy(Trimodality)  with surgery alone . 
o Although the concept is reasonable,  confirmatory result is still 
pending. 
(Urba et al, JCO 2001; Walsh et al, NEJM 1997; Bosset et al, NEJM 
1997; Burmeister et al, Proc.ASCO 2002 ; Malthaner et al, BMC 
Cancer 2004). 
 
 
4.  Brachytherapy: 
xIt is used mainly for palliation when given alone. 
xIt has local control  of 25-35%,  median OS of 5 mos. 
 
RTOG 9207  combined modality(5FU/Cisp/50Gy) followed by intra-luminal  
brachytherapy boost, local failure rate of  27%; acute toxicity Grade 3-5 
58%, 26%, 8% ,respectively; fistula  rate of 18%/yr. ; therefore , at the 
present time brachytherapy is not recommended  by the American 
Brachytherapy Society as a boost when using with high dose rate  
concurrent with chemotherapy. 
 
5.  Chemotherapy: 
x It is used mainly for palliation when given alone. 
x Pre-op chemotherapy may provide small benefit  in survival over 
surgery alone. Confirmative result is pending (Int.0113 study, Thirion et al 
,  Proc ASCO , 2007 ) .  
x Chemotherapy agents for esophageal cancer  include : 
Cisplatinum, most active, >20% response rate.  Others include 5FU, 
Mitomyc. Bleomyc, Doxorub, Vind, Paclit, Vinorel. 
                 5FU + Cisp combination has response  rate of 20-50%. 
 
6. Endoscopic palliation: 
x Laser 
x Ballon dilation 
x Photodynamic 
x Intracavitary irradiation  and   plastic or expandible metal 
prothesis, 
 
all of above is for symptom control only. 
 
 
 
MANAGEMENT SUMMARY : 
Trimodality management of resectable esophageal cancer is evolving, many 
cancer centers favour the neoadjuvant  management ( chemoradiation followed 
by surgery) although  final confirmative result is pending.  
 
There is no clinical trial comparing the benefit of  neoadjuvant VS adjuvant 
resectable esophageal cancer. 
 
 
 
At  London Regional Cancer Program (LRCP) : 
 
Esophageal cancer that is operable, resectable T1-T3 
 The recommended management is: 
x Esophagectomy 
x  After complete resection: 
o If  N0,   the management is  observation only. 
o If  N1,    (or resection margins involvement) the recommended 
management is post -op      chemoradiation. 
 
Esophageal cancer  that is operable, resectable T1-T3
 It is not unreasonable to offer concurrent chemotherapy (5FU/Cisp) + radiation 
therapy (50Gy)   as an alternative treatment option besides surgery ( RTOG 
8501). Survival can approach that of surgery alone in some circumstances. 
 
Esophageal cancer that is inoperable T4, or  surgery refusal 
 The recommended management is concurrent chemoradiation .     
 
 Inoperable  disease and patient  is unable to tolerate chemotherapy , the 
management can be  best supportive care. 
 
 
  Best supportive care includes the following: 
 
o Obstruction-stent, laser, photodynamic therapy. 
o Radiation therapy (xrt )(external beam, brachytherapy). 
o Nutrition - external feeding( J-tube). 
o Pain control - xrt/medications. 
o Bleeding - xrt/surgery/endoscopic therapy. 
 
 
